Forum Europejskie Centrum Integracji i Rozwoju Strona Główna Europejskie Centrum Integracji i Rozwoju
ECID WITA


Puma First Round RP Bayer Invested 10 Puma Espera

 
Napisz nowy temat   Odpowiedz do tematu    Forum Europejskie Centrum Integracji i Rozwoju Strona Główna -> Ogólne
Zobacz poprzedni temat :: Zobacz następny temat  
kah6imi9xy




Dołączył: 22 Lis 2010
Posty: 175
Przeczytał: 0 tematów

Ostrzeżeń: 0/5
Skąd: England

 PostWysłany: Czw 13:00, 16 Gru 2010    Temat postu: Puma First Round RP Bayer Invested 10 Puma Espera Back to top

Scleroderma interferon, by the end of the re-introduction of human insulin and forest. The next five years, is expected to have 20 new products into China.
Bayer Schering Pharma was established in Beijing in 2009, global R & D center, the purpose is to accelerate the introduction of new drugs for the local market and increase market penetration.


Lifestyle changes also will increase health care demand, China has 30 million diabetics, and the smoking population worldwide 1 / 3.

In the past 10 years, the rapid development of Chinese economy and China's urbanization rate is the basis for Bayer to increase the growth rate of about one-fifth of cardiovascular disease deaths occur in China. The proportion of cancer deaths in China are similar. Currently, about 30 million people died of liver cancer each year in the United States, 24 are,

This can not only use Bayer and local hospitals and research institutions "integrated" network of researchers, so that more Chinese patients were involved in early clinical trials, but also so that more medical research and development outsourcing (CRO) more frequent cooperation eventually speed up the approval process for new drugs in China, and the market.

Bayer is currently in China, one of the top three foreign pharmaceutical companies, diabetes care, cardiovascular disease treatment business in a leading position. In 2009, the company's sales in China 530 million euros, an increase of 28%. An increase of more than four years ago, 7 times. Only one of which is approved for use pre-diabetes drug Acarbose treatment of oral hypoglycemic sales last year rose 28% to 143 million euros. Other cardiovascular medications Adalat 39% of sales in 2009, 1.01 billion euros.

Chemical Network News, 27 April, the German pharmaceutical group Bayer subsidiary Bayer Schering Pharma announced that 2010 will be published in the Chinese market four drugs. Continues to accelerate the advance in the Chinese market and invest in the next 5 years, 100 million euros for the development of new drugs for the Chinese market.



Drugs as China declared a non-independent countries, imported drugs need to have reference to State approval to declare the import. Europe and the United States and other developed countries over the past listed drugs are generally 7-8 years in order to enter the Chinese market, and some even longer.

According to McKinsey (McKinsey) predicted that by 2020 more than 50 years old and 50-year-old population will reach 5 billion yuan.
It is understood that Bayer is expected in the Chinese market for the new product portfolio, including cancer, heart failure, breast cancer, and other products will be available in August this year, for multiple

Bayer Schering Pharma China / Hong Kong Island and the Chinese president Li Xilie Bayer HealthCare, said: "Given China's pharmaceutical market growth rate of 20% per year, Bayer expects the Chinese market contribution to global business in 2013 to 29%. "current contribution rate of about 10%.
2009, Bayer Schering Pharma R & D centers in China, and Shanghai Institute of Organic Chemistry, Tsinghua University and other cooperation [link widoczny dla zalogowanych], through local experts in biological sciences and chemical R & D, to its product line [link widoczny dla zalogowanych], and tumors, women health, cardiology and other diagnostic imaging and is focused on areas of cooperation.
Now Bayer Schering Pharma new drug approval process is expected to be reduced to 1 year or less.

According to Bayer Schering Pharma China [link widoczny dla zalogowanych], Wang Min, director of medical department of introduction, this "integrated development" strategy is characterized by the largest clinical activities so that more can be carried out in China. "2010, due to the establishment of independent regional structure, Bayer R & D center in China to carry out clinical trials has increased significantly. From 2005 to three

相关的主题文章:


[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]

[link widoczny dla zalogowanych]


Post został pochwalony 0 razy
 
Zobacz profil autora
Wyświetl posty z ostatnich:   
Napisz nowy temat   Odpowiedz do tematu    Forum Europejskie Centrum Integracji i Rozwoju Strona Główna -> Ogólne Wszystkie czasy w strefie EET (Europa)
Strona 1 z 1

 
Skocz do:  
Możesz pisać nowe tematy
Możesz odpowiadać w tematach
Nie możesz zmieniać swoich postów
Nie możesz usuwać swoich postów
Nie możesz głosować w ankietach

Cobalt 2.0 phpBB theme/template by Jakob Persson.
Copyright © 2002-2004 Jakob Persson


fora.pl - załóż własne forum dyskusyjne za darmo
Powered by phpBB © 2001, 2002 phpBB Group